SpyGlass CEO granted 300,000 stock options

SpyGlass Pharma, Inc. Chief Executive Officer and director Patrick H. Mooney reported the acquisition of a stock option grant for 300,000 shares of common stock.

Rhea-AI Filing Summary

SpyGlass Pharma, Inc. Chief Executive Officer and director Patrick H. Mooney reported the acquisition of a stock option grant for 300,000 shares of common stock. The option has an exercise price of $16 per share and is held as a direct ownership position.

The grant vests over four years starting from a vesting commencement date of February 5, 2026. Twenty-five percent of the shares vest on the one-year anniversary of that date, and the remaining shares vest in equal monthly installments thereafter, contingent on Mr. Mooney continuing as a service provider.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Mooney Patrick H.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	300,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 300,000 contracts (Direct)

Footnotes (1)

1. F1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

FAQ

What insider transaction did SpyGlass Pharma (SGP) report for Patrick H. Mooney?

SpyGlass Pharma reported that CEO and director Patrick H. Mooney acquired a stock option grant for 300,000 shares of common stock. The transaction is coded as a grant or award acquisition and is reported as a derivative security on a Form 4 filing.

What are the key terms of Patrick H. Mooney’s 300,000 SpyGlass Pharma (SGP) options?

Patrick H. Mooney received stock options covering 300,000 shares of SpyGlass Pharma common stock at a $16 exercise price per share. The options are reported with zero cost for the grant itself and are classified as directly owned derivative securities.

How do Patrick H. Mooney’s SpyGlass Pharma (SGP) options vest over time?

The options begin vesting from a February 5, 2026 vesting commencement date. Twenty‑five percent vest on the one‑year anniversary, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service.

What role does continued service play in Patrick H. Mooney’s SGP option vesting?

Vesting of Patrick H. Mooney’s options is conditioned on him continuing as a service provider under SpyGlass Pharma’s 2026 Equity Incentive Plan. If service ends, unvested portions would stop vesting according to the plan’s terms referenced in the filing.

How many SpyGlass Pharma (SGP) derivative securities does Patrick H. Mooney hold after this grant?

After the reported grant, Patrick H. Mooney beneficially owns 300,000 derivative securities in the form of stock options. These options provide the right to purchase an equal number of SpyGlass Pharma common shares at the specified exercise price.

Is Patrick H. Mooney’s ownership in SpyGlass Pharma (SGP) direct or indirect for this option grant?

The filing classifies Patrick H. Mooney’s ownership of the 300,000 stock options as direct. No indirect ownership entity or separate nature of indirect beneficial ownership is identified for this specific derivative security position in the report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/09/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mooney Patrick H.

(Last) (First) (Middle)

C/O SPYGLASS PHARMA, INC.

27061 ALISO CREEK RD., SUITE 100

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SpyGlass Pharma, Inc. [ SGP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16	02/05/2026		A		300,000		(1)	02/05/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 5, 2026.

	/s/ Brian Aukshunas, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.